Add Yahoo as a preferred source to see more of our stories on Google. Difficulty balancing or an inability to do so can be caused by any number of factors. Head injuries, migraines, alcohol use, ear ...

If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

Patients with Friedreich’s ataxia experience progressive loss of coordination, muscle weakness, and fatigue, which commonly progresses to motor incapacitation and wheelchair reliance by their teens or ...

Topline results show eDSP failed to significantly improve RmICARS scores in ataxia-telangiectasia patients compared with placebo in the NEAT trial.

Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.

Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.

Researchers confirm the need for cardiac follow-up in patients with Friedreich ataxia, with particular focus on left ventricular ejection fraction (LVEF) as a predictor of worse prognosis. They ...

Difficulty balancing or an inability to do so can be caused by any number of factors. Head injuries, migraines, alcohol use, ear infections and medications can all affect your musculoskeletal system ...